Sharing Responses to Health Canada’s Patented Medicines Regulations Consultation
In May 2017, Federal Minister of Health Jane Philpott, launched a consultation on proposed amendments to the Patented Medicines Regulations that would have significant effects on how patented drug prices are regulated in Canada. The consultation period closed June 28, 2017.
While a summary of comments received in the consultation will be published in the Regulatory Impact Analysis Statement at Canada Gazette Part I in the fall, the submissions will not be shared publicly in their entirety.
To facilitate transparency during this time of unprecedented change, PDCI is hosting this page where stakeholders are invited to share their consultation submissions with one another and the public.
If you or your organization responded to Health Canada’s Consultation on Proposed Amendments to the Patented Medicines Regulations and are interested to share your response with the public and stakeholder community please contact PDCI’s Managing Director, Kaitlyn Proulx at Kaitlyn.Proulx@pdci.ca or (613) 742-8225 ext. 33.
- Draft prepared and coordinated by Myeloma Canada and Save Your Skin Foundation and endorsed by 18 Patient Organizations:
- Canadian Cancer Survivor Network (CCSN)
- Canadian Psoriasis Network
- Canadian Spondylitis Association
- Carcinoid-NeuroEndocrine Tumor Society (CNETs)
- Collective Oncology Network for Exchange, Innovation in Cancer Care, Treatment Access and Education (CONECTed)
- Hep C BC
- Lifesaving Therapies Network
- Lung Cancer Canada
- Lymphoma Canada
- Melanoma Network of Canada
- Myeloma Canada
- Ontario Caregiver Coalition
- Rethink Breast Cancer
- Save Your Skin Foundation
- Schizophrenia Society of Ontario (SSO)
- Sickle Cell Awareness Group of Ontario (SCAGO)
- Sickle Cell Disease Association of Canada (SCDAC)
- The Lung Association Ontario
- Aidan Hollis
- AstraZeneca Canada
- Bayer Inc.
- Best Medicines Coalition
- Canadian Association of PNH Patients
- Canadian Organization for Rare Disorders
- Coalition canadienne des organismes de bienfaisance en santé Sommaire
- Diabetes Canada
- GlaxoSmithKline Inc.
- Health Charities Coalition of Canada – English
- Innovative Medicines Canada
- Joel Lexchin MD
- Johnson & Johnson
- Life Sciences Ontario, BioAlberta, Montréal InVivo
- Merck Canada Inc.
- PDCI Market Access Inc.
- Roche Canada
Please be advised:
- The views and opinions expressed in the consultation submissions on this page are solely those of the author and DO NOT represent those of PDCI Market Access.
- This page is intended to be a repository of submissions for the purpose of information sharing. It is not intended to promote or lobby on behalf of any specific stakeholder, individual, group or interest.
- PDCI has accepted no funds whatsoever to support this initiative.
- PDCI is welcoming submissions from ALL individuals, stakeholders, groups, etc. who made submissions as part of Health Canada’s Consultation of Proposed Amendments to the Patented Medicines Regulations, however this repository is not comprehensive. PDCI is making efforts to reach all stakeholder communities who may have submitted to make them aware of this repository and to provide information on how to be included, if desired. PDCI will continue to post new submissions as they are received.
- PDCI is unable to verify the identity of stakeholders who made submissions, nor the content of those submissions. In hosting this website, PDCI therefore assumes that those who have provided PDCI their submissions for inclusion in this repository have done so in good faith and have provided PDCI with the submission identical to that which they provided to Health Canada for purposes of the consultation.
- To the best of PDCI’s knowledge, all submissions have been prepared independently and/or authors of submissions have appropriately disclosed any conflicts of interest within their submissions.
- PDCI cannot be held responsible for the content of any submissions including but not limited to any inaccurate information.